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Purpose of the study
The benefit of newer antiretroviral regimens on clinical
end-points for treatment-experienced, HIV-1-infected
patients remains to be determined. Etravirine (ETR) dem-
onstrated durable efficacy and safety in HIV-1 infected,
treatment-experienced patients in the phase III DUET tri-
als. We report adjudicated clinical end-points from a pre-
specified pooled analysis of DUET-1 and DUET-2 after 48
weeks of treatment.
Methods
Patients were randomised 1:1 to receive either ETR 200
mg BID or placebo, both in combination with a back-
ground regimen of darunavir/r, investigator-selected nucl-
eoside reverse transcriptase inhibitors and optional
enfuvirtide (ENF). AIDS-defining events/deaths (ADE/D)
were adjudicated by a 4-member independent panel
masked to treatment assignment. All events were adjudi-
cated, and only those confirmed or probable ADE/D were
included in the analysis. Pre-specified analyses were strat-
ified by de novo or not de novo (including recycled ENF or
ENF not used) ENF use.
Summary of results
599 and 604 patients received ETR and placebo, with
median treatment duration of 52.3 vs 51.0 weeks, respec-
tively. At baseline, median CD4 cell count was 105 cells/
mm3, log10 HIV-RNA was 4.8 and 59% had clinical CDC
C classification. Overall, 35 ETR patients (5.8%) and 59
placebo patients (9.8%) had an ADE/D (p = 0.041). In
total, 22 ADE/D occurred in the first 30 days (six in the
ETR group, 16 in the placebo group). Time to ADE/D was
significantly shorter for patients in the placebo group
compared with ETR (Figure 1). The most common ADEs
were Candida esophagitis (one ETR, 10 placebo), Pneumo-
cystis pneumonia (three ETR, six placebo), Mycobacterium
avium complex (two ETR, seven placebo), herpes simplex
virus (four ETR, four placebo), cytomegalovirus retinitis
(one ETR, six placebo) and Kaposi's sarcoma (two ETR,
four placebo). In the de novo ENF sub-group (ETR n = 153;
placebo n = 159), events were similar, with an ADE/D
reported for 11 patients in the ETR group (7.2%) and 14
patients in the placebo group (8.8%). However, in those
not receiving de novo ENF (ETR n = 446; placebo n = 445),
more events among patients in the placebo group were
reported than among those in the ETR group (45 patients
[10.1%] vs. 24 patients [5.4%]; p = 0.0086).
Conclusion
In addition to virological and immunological benefits,
use of ETR was associated with a reduction in ADE/D and
a significantly longer time to ADE/D than placebo in treat-
ment-experienced, HIV-1-infected patients.
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